Beranda › Limfoma Folikuler › Maryland › Baltimore
Uji klinis Limfoma Folikuler di Baltimore, MD
4 studi untuk Limfoma Folikuler mencari peserta di lokasi sekitar Baltimore (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Menerima pesertaFase 3
- Research Site, Baltimore
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Menerima pesertaFase 3
- Local Institution - 0023, Baltimore
- Greater Baltimore Medical Center, Towson · 8 mi jauhnya
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Menerima pesertaFase 1
- University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · 8 mi jauhnya
Uji klinis Limfoma Folikuler di kota lain
- New York City, NY24 studi
- Milwaukee, WI19 studi
- Nashville, TN18 studi
- Houston, TX18 studi
- Boston, MA17 studi
- Baldwin Park, CA16 studi
- Seattle, WA15 studi
- Durham, NC15 studi
- Columbus, OH13 studi
- Salt Lake City, UT13 studi
- Chicago, IL12 studi
- San Antonio, TX12 studi
Studi lain di Baltimore
- Kanker Paru Non-Sel Kecil60 studi
- Kanker Payudara47 studi
- Kanker Prostat43 studi
- Kanker Paru40 studi
- Kanker (semua jenis)37 studi
- Kanker Kolorektal31 studi
- Kanker Pankreas31 studi
- Kanker Metastatik28 studi
- Obesitas25 studi
- Gagal Jantung24 studi
- Kanker Kandung Kemih24 studi
- Stroke22 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.